Abstract
Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
Current Molecular Medicine
Title: Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects
Volume: 9 Issue: 6
Author(s): Sarah Church, Bernard A. Fox, Walter J. Urba, Brendan D. Curti, Hong-Ming Hu, Todd S. Crocenzi, Sidney Rosenheim, Andrew D. Weinberg, Emmanuel Akporiaye, Edwin B. Walker, Daniel P. Haley, Elisa Cardenas, Ulf Petrausch, Kevin Friedman, Levi Maston, Tarsem Moudgil, Michael G. LaCelle, Sachin Puri, Ilka Assmann, James A. Thompson, Chris Twitty, Shawn M. Jensen and Christian H. Poehlein
Affiliation:
Abstract: Since multiple lines of experimental and clinical data clearly identified regulatory T cells as an integral part of the immune response, these cells have become a major focus of investigation in tumor immunology. Regulatory T cells are in place to dampen ongoing immune responses and to prevent autoimmunity, but they also have profound effects in blocking therapeutic anti-tumor activity. Therefore regulatory T cells are seen as a major hurdle that must be overcome in order for cancer immunotherapy to reach its therapeutic potential. Regulatory T cells are heterogeneous with sub-populations that exhibit distinct functional features. Here we will review the individual sub-populations in regards to their mode of action and their potential impact on blocking anti-tumor immunity. Approaches to measure function and frequency of regulatory T cells in model systems and clinical trails will be discussed. Finally, we will describe possible ways to interfere with regulatory T cell-mediated immune suppression with the focus on recent pre-clinical and clinical findings.
Export Options
About this article
Cite this article as:
Church Sarah, Fox A. Bernard, Urba J. Walter, Curti D. Brendan, Hu Hong-Ming, Crocenzi S. Todd, Rosenheim Sidney, Weinberg D. Andrew, Akporiaye Emmanuel, Walker B. Edwin, Haley P. Daniel, Cardenas Elisa, Petrausch Ulf, Friedman Kevin, Maston Levi, Moudgil Tarsem, LaCelle G. Michael, Puri Sachin, Assmann Ilka, Thompson A. James, Twitty Chris, Jensen M. Shawn and Poehlein H. Christian, Cancer Immunotherapy: The Role Regulatory T Cells Play and What Can be Done to Overcome their Inhibitory Effects, Current Molecular Medicine 2009; 9 (6) . https://dx.doi.org/10.2174/156652409788970670
DOI https://dx.doi.org/10.2174/156652409788970670 |
Print ISSN 1566-5240 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5666 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Virtual Screening of Acetylcholinesterase Inhibitors Based on Machine Learning Combined with Molecule Docking Methods
Current Bioinformatics Serum Biochemical Markers of Brain Injury
Mini-Reviews in Medicinal Chemistry Targeted Angiogenesis Therapy in Head and Neck Squamous Cell Carcinomas
Current Angiogenesis (Discontinued) The Human Glioma-Associated Oncogene Homolog 1 (GLI1) Family of Transcription Factors in Gene Regulation and Diseases
Current Genomics Potential Gene Therapy Strategies for Cancer Stem Cells
Current Gene Therapy Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine New Approaches to Target Cancer Stem Cells: Current Scenario
Mini-Reviews in Medicinal Chemistry The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Multiple VEGF Family Members are Simultaneously Expressed in Ovarian Cancer: a Proposed Model for Bevacizumab Resistance
Current Pharmaceutical Design CXCR4 and CXCL12 Expression in Rectal Tumors of Stage IV Patients Before and After Local Radiotherapy and Systemic Neoadjuvant Treatment
Current Pharmaceutical Design Emerging Role of Circular RNAs in Kidney Diseases in Nephrology
Current Drug Targets Clinical Trials of Targeted Alpha Therapy for Cancer
Reviews on Recent Clinical Trials The FKBP51-Glucocorticoid Receptor Balance in Stress-Related Mental Disorders
Current Molecular Pharmacology Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Association of Posture Instability with Dopamine Drop of Nigrostriatal System and Hypometabolism of Cerebral Cortex in Parkinson’s Disease
Current Neurovascular Research Neural Differentiation and Therapeutic Potential of Adipose Tissue Derived Stem Cells
Current Stem Cell Research & Therapy Therapeutic Potential of Peptide Toxins that Target Ion Channels
Inflammation & Allergy - Drug Targets (Discontinued) Phytoestrogens and Mitochondrial Biogenesis in Breast Cancer. Influence of Estrogen Receptors Ratio
Current Pharmaceutical Design Vascular Endothelial Growth Factor (VEGF) Signaling in Tumour Vascularization: Potential and Challenges
Current Vascular Pharmacology The Evolving Landscape in the Development of Isocitrate Dehydrogenase Mutant Inhibitors
Mini-Reviews in Medicinal Chemistry